This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
McGuire WP , Blessing JA , Bookman MA , Lentz SS , Dunton CJ
Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study
Journal of Clinical Oncology. 2000 Mar;18(5) :1062-1067
AbstractPurpose: Topotecan is known to be active in recurrent ovarian cancer, but most prior studies have focused on platinum- resistant or refractory populations. This study was undertaken ta define the response rate and progression-free interval in platinum-sensitive patients. Patients and Methods: Patients with recurrent ovarian cancer after one or two prior chemotherapy regimens and in whom the interval between prior platinum therapy and the initiation of protocol therapy wets greater than 6 months were treated with topotecan 1.5 mg/m(2) intravenously over 30 minutes daily for 5 days, with this cycle repeated every 21 days. Results: Forty-eight patients were entered onto the study; 47 were assessable for toxicity and 46 for response. The response rate was 33% (two complete responses and 13 partial responses), with a median response duration of 11.2 months. Hematologic toxicity predominated but was manageable in most patients with frequent incorporation of cytokines and RBC and platelet transfusions. Fatigue was reported in 15 patients and resulted in the discontinuation of therapy in five responding patients. Conclusion: Topotecan is an active drug in platinum-sensitive ovarian cancer, with significant but manageable hematologic toxicity. Fatigue is also a common problem that may be dose-limiting in some patients. J Clin Oncol 18:1062-1067. (C) 2000 by American Society of Clinical Oncology.
NotesTimes Cited: 39 English Article 288VW J CLIN ONCOL